Skip to main content
OpenTrials
Completed

NCT Number: NCT06737367

Integrating Machine Learning for Prognostic Prediction in Stage I NSCLC by CT Images and Pathological Factors

The investigators retrospectively collected the participants with stage I non-small cell lung cancer (NSCLC) patients resected between January 2010 to December 2020 for training and internal validation. The Clinical data, preoperative clinical information, laboratory results and CT images were collected. The investigators also collected the disease-free survival time. On the Deepwise multi-modal research platform, the images were semi-automatically segmented and expanded outward by 3mm to obtain the peritumor tissue. PyRadiomics was used to extract the radiomic features. LASSOcox and rsf were used to select the features. we developed a machine learning-based integrative prognostic model that utilizes radiomic and pathological variables as input using LOOCV framework. And it was further tested on the internal and external cohorts. Discrimination was assessed by using the C-index and area under the receiver operating characteristic curve (AUC), IBS, DCA.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Jinling Hospital, China

Nanjing, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients with stage I NSCLC (ninth AJCC edition) who underwent curative R0 resections between January 2010 and December 2020 -

Exclusion criteria

  • absence of enhanced CT
  • history of lung cancer or synchronous lung cancers
  • follow-up records ≤3 Months
  • carcinoma in situ (CIS) or minimally invasive NSCLC
  • death within 30 days of surgery
  • no pathological slides or reports

Treatment and study plan

CT radiomic analysis

Other

Radiomic features of tumor and peritumor tissue

Primary outcomes

  1. DFS(Disease-free survival)

    Time frame: Record from the date of surgery to the date of recurrence or death from any cause, whichever comes first, and assess up to a maximum of 5 years.

    DFS was defined as the duration from the date of primary surgery to the first occurrence of recurrence or death from any cause.

Sponsors and collaborators

Lead sponsor

Jinling Hospital, China

Other

Registry information

Official study title

Integrating Machine Learning for Prognostic Prediction in Stage I NSCLC: a Multicenter Analysis

Acronym: Stage I NSCLC

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Dec 17, 2024
Registry last updated
Dec 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.